Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions

Next Previous
Trial Profile

A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erdafitinib (Primary)
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Janssen Pharmaceutical KK

Most Recent Events

  • 09 Jan 2025 Status changed from recruiting to active, no longer recruiting.
  • 07 Aug 2024 According to a BeiGene media release. results demonstrating encouraging response rates, durable responses and manageable safety profiles as monotherapy in R/R WM, were presented in EHA 2024.
  • 23 Apr 2024 Planned End Date changed from 30 Jul 2027 to 24 Sep 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top